Artivila Therapeutics

Shenzhen, China· Est. 2018

Clinical-stage biotech using AI-powered drug discovery to develop first-in-class therapies for autoimmune diseases, neurodegenerative disorders, and cancers.

artivila.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Estimated funding: $42M

AI Company Overview

Clinical-stage biotech using AI-powered drug discovery to develop first-in-class therapies for autoimmune diseases, neurodegenerative disorders, and cancers.

OncologyImmunology

Technology Platform

Proprietary integrated platform combining Artificial Intelligence-Driven Drug Discovery (AIDD) and Computer-Aided Drug Design (CADD) for accelerated identification and optimization of novel drug candidates.

Opportunities

Significant opportunity to validate AI-driven drug discovery platform through clinical success of ARD-885, potentially enabling expansion into additional autoimmune and oncology indications.

Growing demand for innovative therapies in China's pharmaceutical market.

Risk Factors

Clinical development risks for lead asset ARD-885, competition from established pharmaceutical companies and other AI-driven biotechs, and dependence on continued funding to advance pipeline programs.

Competitive Landscape

Competes with traditional pharma companies and other AI-driven biotechs like Exscientia, Recursion, and Insilico Medicine; differentiation comes from integrated AIDD/CADD platform and focus on first-in-class therapies for autoimmune and neurodegenerative diseases.

More companies in China →